Quantcast
Last updated on April 18, 2014 at 15:11 EDT

Latest Glioma Stories

2013-07-02 08:27:37

HEIDELBERG, Germany, July 2, 2013 /PRNewswire/ -- Apogenix GmbH, a clinical stage biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases, announced today that it was able to expand the patent protection for its lead product candidate Apocept(TM) (APG101). The company was recently granted two patents that cover the medical use of Apocept (APG101) in Europe and Canada. The European patent protects the medical use of CD95...

2013-06-25 23:24:31

Westchester County Hospital Performs Advanced Stereotactic Radiosurgery with Perfexion Mt. Kisco, New York (PRWEB) June 25, 2013 Northern Westchester Hospital announced today that it has become the only facility between Manhattan and Syracuse, NY to offer patients advanced head and neck cancer treatment using the latest and most advanced system for stereotactic radiosurgery. The Gamma Knife Perfexion is considered the gold standard for the non-invasive treatment of a variety of cancerous...

2013-06-25 23:23:11

Voices Against Brain Cancer, an organization dedicated to brain cancer research and advocacy, comments on the recent discovery of a virus combination that has proven to be effective against deadly brain tumors. New York, NY (PRWEB) June 25, 2013 On June 25, Voices Against Brain Cancer, an organization dedicated to brain cancer research and advocacy, comments on the recent discovery of a combination of viruses that has proven to be effective against the deadliest forms of brain tumors....

2013-06-19 08:30:22

NEW YORK, June 19, 2013 /PRNewswire/ -- Voices Against Brain Cancer (VABC), a not-for-profit organization dedicated to finding a cure for brain cancer, today announced that it has awarded Tocagen Inc. (www.tocagen.com) a grant to support the clinical investigation of Toca 511 & Toca FC in patients diagnosed with a recurrent high grade glioma brain cancer (Grade 3 or Grade 4). Tocagen is a privately held biopharmaceutical company developing novel treatments for advanced cancer, with an...

2013-06-17 16:25:25

Dr. Frank Tufaro to present first-in-human clinical data demonstrating DNX-2401's ability to treat patients with malignant brain tumors HOUSTON, June 17, 2013 /PRNewswire/ -- DNAtrix Inc., experts in oncolytic virus development, today announced that its CEO will present clinical data on the company's lead product, DNX-2401, at the Replicating Oncolytic Virus Therapeutic meeting in Quebec City, Canada on June 18, 2013. Dr. Frank Tufaro, DNAtrix's CEO and a leader in the field of...

2013-06-12 12:28:27

VISIUS(®) Surgical Theatre iMRI brings increased tumor resection and limits patient risks MINNEAPOLIS, MN, June 12, 2013 /PRNewswire/ - IMRIS Inc. (NASDAQ: IMRS; TSX: IM) ("IMRIS" or the "Company") today announced that University Hospital Tübingen neurosurgeons in Tübingen, Germany, are reporting success toward their objectives of limiting patient risk and improving surgical precision using intraoperative MRI for brain surgery procedures in the...

2013-06-10 08:29:29

Company invites individual and institutional investors to log-on to view presentation NEW YORK, June 10, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) today announced that their June 6(th) RetailInvestorConferences.com presentation is now available for on-demand viewing. LINK: www.retailinvestorconferences.com > click on the red "register/ watch event now" button DelMar Pharmaceuticals, Inc.'s presentation will be available 24/7 for 90 days. Investors may...

2013-06-07 23:01:12

Voices Against Brain Cancer, an organization dedicated to brain cancer research and advocacy, comments on a new discovery made by researchers in regards to the tie between brain cancer and genetics. New York, NY (PRWEB) June 07, 2013 On June 7, Voices Against Brain Cancer, an organization dedicated to brain cancer research and advocacy, comments on the recent discovery made by researchers in regards to the tie between brain cancer and genetics. According to a redOrbit.com article, the...

2013-06-04 08:30:56

BUFFALO, N.Y., June 4, 2013 /PRNewswire/ -- Kinex Pharmaceuticals, Inc. announced today, that the FDA has allowed its Investigational New Drug (IND) application for KX02, Kinex's dual src/pretubulin inhibitor for the glioblastoma setting. KX02 is partnered in the greater China territory with XiangXue Pharmaceuticals (300147.SZ) of Guangzhou, China. KX02 is Kinex's second internally developed compound to enter clinical studies and Phase I clinical protocols are being finalized...

Genetic Traits Of Cells Responsible For One Type Of Brain Cancer Discovered
2013-06-04 08:32:15

redOrbit Staff & Wire Reports — Your Universe Online The genetic traits of glial cells -- the cells which give rise to the most common form of malignant brain cancer in humans -- have been identified by a team of researchers led by University of Rochester Medical Center (URMC) neurologist Dr. Steven Goldman. “This study identifies a core set of genes and pathways that are dysregulated during both the early and late stages of tumor progression,” Goldman, senior...